Motif Bio Plc (MTFB):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Motif Bio Plc (MTFB) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C9366
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:55
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:イギリス
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Motif Bio Plc (Motif Bio), formerly Motif Bio Ltd, is a clinical-stage biopharmaceutical company that focuses on the development of novel antibiotics to treat patients with infections caused by multi-drug resistant bacteria. The company develops Iclaprim, a targeted Gram-positive1 antibiotic with activity against methicillin-resistant Staphylococcus aureus. Its indications for iclaprim include hospital-acquired bacterial pneumonia (HABP) including ventilator-associated bacterial pneumonia (VABP) and Staphylococcus aureus lung infections in people with cystic fibrosis. The company has operations in the UK and the US. Motif Bio is headquartered in London, the UK.

Motif Bio Plc (MTFB) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Motif Bio Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Motif Bio Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Motif Bio Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Motif Bio Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Motif Bio Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Motif Bio Plc, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
Motif Bio Enters into Agreement with Covance 11
Motif BioSciences Enters Into Co-Development Agreement With Jubilant Biosys 12
Merger 13
Motif Biosciences to Merge with Pharmaceutical Company 13
Equity Offering 14
Motif Bio Raises USD13.5 Million in Private Placement of Shares 14
Motif Bio Raises Funds through Private Placement of Shares up on Exercise of Warrants 15
Motif Bio Raises Funds through Private Placement of Shares up on Exercise of Warrants 16
Motif Bio Files Registration Statement to Raise up to USD80 Million in Public Offering of Securities 17
Motif Bio Files Registration Statement to Raise Funds through Private Placement of ADS upon Exercise of Warrants 18
Motif Bio to Raise USD0.1 Million in Public Offering of Shares up on Exercise of Warrants 19
Motif Bio to Raise USD25 million in Placing of New Ordinary Shares 20
Motif Bio Raises Funds through Private Placement of Shares and Warrants 21
Motif Bio Raises USD17 Million in Public Offering of American Depositary Shares and Warrants 23
Motif Bio Raises Funds through Private Placement upon Exercise of Warrants 25
Motif Bio Raises Funds in Private Placement upon Exercise of Warrants 26
Motif Bio Raises USD35 Million in Private Placement of Shares 27
Motif Bio Raises USD41.8 Million in IPO 28
Debt Offering 29
Motif Bio to Raise USD20 Million in Private Placement of Debt Financing 29
Acquisition 30
Motif BioSciences Acquires Nuprim 30
Motif Bio Plc – Key Competitors 31
Motif Bio Plc – Key Employees 32
Motif Bio Plc – Locations And Subsidiaries 33
Head Office 33
Other Locations & Subsidiaries 33
Recent Developments 34
Financial Announcements 34
Sep 25, 2018: Motif Bio announces Half-Year 2018 financial results and operational progress 34
Apr 10, 2018: Motif Bio Reports Fiscal Year 2017 Results 35
Sep 29, 2017: Motif Bio reports half-year 2017 financial results and operational progress 39
May 01, 2017: Motif Bio Reports Year-End 2016 Financial Results 40
May 01, 2017: Motif Bio annual net loss up 41
Corporate Communications 42
Jul 03, 2018: Motif Bio Announces Resignation of Robert Bertoldi from Board of Directors 42
Feb 02, 2018: Motif Bio Appoints Jonathan E. Gold As Interim Chief Financial Officer 43
May 10, 2017: Motif Bio Appoints Scientific Opinion Leaders to Advisory Board 44
May 05, 2017: Motif Bio Appoints Dr. Craig Albanese as Non-Executive Director 45
Jan 17, 2017: Motif Bio: Appointment of Chief Financial Officer 46
Government and Public Interest 47
Jan 29, 2018: Motif Bio, Spero Therapeutics and Vical Join Antimicrobials Working Group 47
Product News 48
06/22/2017: Motif Bio Invited to Present at Infectious Diseases Conference 48
Clinical Trials 49
Aug 09, 2017: Motif Bio’s second Phase 3 clinical trial in ABSSSI finishes patient treatment phase 49
Jul 06, 2017: Motif Bio to Present Three Posters at IDWeek 2017 50
May 01, 2017: Motif Bio Reports Year-end 2016 Financial Results 51
Apr 18, 2017: Motif Bio Announces Positive Results For Iclaprim, In The Revive-1 Phase 3 Study 52
Jan 30, 2017: Motif Bio Phase 3 Clinical Trial Finishes Patient Treatment Phase 53
Other Significant Developments 54
Mar 13, 2018: Motif Bio: Change of Registered Office 54
Appendix 55
Methodology 55
About GlobalData 55
Contact Us 55
Disclaimer 55

List of Tables
Motif Bio Plc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Motif Bio Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Motif Bio Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Motif Bio Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Motif Bio Plc, Deals By Therapy Area, 2012 to YTD 2018 9
Motif Bio Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Motif Bio Enters into Agreement with Covance 11
Motif BioSciences Enters Into Co-Development Agreement With Jubilant Biosys 12
Motif Biosciences to Merge with Pharmaceutical Company 13
Motif Bio Raises USD13.5 Million in Private Placement of Shares 14
Motif Bio Raises Funds through Private Placement of Shares up on Exercise of Warrants 15
Motif Bio Raises Funds through Private Placement of Shares up on Exercise of Warrants 16
Motif Bio Files Registration Statement to Raise up to USD80 Million in Public Offering of Securities 17
Motif Bio Files Registration Statement to Raise Funds through Private Placement of ADS upon Exercise of Warrants 18
Motif Bio to Raise USD0.1 Million in Public Offering of Shares up on Exercise of Warrants 19
Motif Bio to Raise USD25 million in Placing of New Ordinary Shares 20
Motif Bio Raises Funds through Private Placement of Shares and Warrants 21
Motif Bio Raises USD17 Million in Public Offering of American Depositary Shares and Warrants 23
Motif Bio Raises Funds through Private Placement upon Exercise of Warrants 25
Motif Bio Raises Funds in Private Placement upon Exercise of Warrants 26
Motif Bio Raises USD35 Million in Private Placement of Shares 27
Motif Bio Raises USD41.8 Million in IPO 28
Motif Bio to Raise USD20 Million in Private Placement of Debt Financing 29
Motif BioSciences Acquires Nuprim 30
Motif Bio Plc, Key Competitors 31
Motif Bio Plc, Key Employees 32
Motif Bio Plc, Subsidiaries 33

List of Figures
Motif Bio Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Motif Bio Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Motif Bio Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Motif Bio Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Motif Bio Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Motif Bio Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Motif Bio Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Motif Bio Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[Motif Bio Plc (MTFB):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • HMicro Inc-医療機器分野:企業M&A・提携分析
    Summary HMicro Inc (HMicro) is a medical device company that offers wireless sensor solutions. The company offers REACH wireless module, a wireless silicon platform that offers fully disposable and wearable wireless sensor patches for a range of professional clinical procedures in hospitals, clinics …
  • SmarTone Telecommunications Holdings Ltd (315):企業の財務・戦略的SWOT分析
    SmarTone Telecommunications Holdings Ltd (315) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key str …
  • Bristow Group Inc:企業の戦略・SWOT・財務分析
    Bristow Group Inc - Strategy, SWOT and Corporate Finance Report Summary Bristow Group Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Tompkins Financial Corp (TMP):企業の財務・戦略的SWOT分析
    Tompkins Financial Corp (TMP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • Curis Inc (CRIS):製薬・医療:M&Aディール及び事業提携情報
    Summary Curis Inc (Curis) is a biotechnology company that focuses on developing and commercializing novel drug candidates for treating human cancers with substantial unmet medical need. It has three drug candidates in development, CUDC-907 for diffuse large B-cell lymphoma (DLBCL) and solid tumors; …
  • Petrobras Argentina SA:石油・ガス:M&Aディール及び事業提携情報
    Summary Petrobras Argentina SA (PESA), a subsidiary of Pampa Energia S.A, is an integrated energy company. It carries out the exploration and production of crude oil and natural gas, refining of crude oil, transportation, and marketing of oil and refined products. The company’s product portfolio inc …
  • Etrion Corp (ETX):企業の財務・戦略的SWOT分析
    Summary Etrion Corp (Etrion) formerly PetroFalcon Corp, is a solar energy development company. The company produce power and builds, owns and operates utility-scale solar power generation plants. It develops greenfield solar power projects in Japan and Chile. Etrion owns and operates 56.7 MW of sola …
  • Ark Restaurants Corp. (ARKR):企業の財務・戦略的SWOT分析
    Ark Restaurants Corp. (ARKR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Pharmicell Co Ltd (005690):製薬・医療:M&Aディール及び事業提携情報
    Summary Pharmicell Co Ltd (Pharmicell), formerly Yuhaw Trade Co Ltd is a biopharmaceutical company that discovers, develops, and commercializes stem cell drugs. The company offers pipeline products such as Cellgram_AMI a heart disease drug, Cellgram_Lung a pulmonary disease drug, and Cellgram_IS and …
  • UNIQA pojistovna, a.s.:企業の戦略・SWOT・財務情報
    UNIQA pojistovna, a.s. - Strategy, SWOT and Corporate Finance Report Summary UNIQA pojistovna, a.s. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Landstar System, Inc.:企業の戦略・SWOT・財務分析
    Landstar System, Inc. - Strategy, SWOT and Corporate Finance Report Summary Landstar System, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Coty Inc.:企業の戦略・SWOT・財務分析
    Coty Inc. - Strategy, SWOT and Corporate Finance Report Summary Coty Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions …
  • ImmusanT Inc-医療機器分野:企業M&A・提携分析
    Summary ImmusanT Inc (ImmusanT) is a drug company that discovers and develops therapies for celiac disease. The company’s pipeline products include Nexvax 2 and Nexvax 3. Its pipeline product Nexvax 2 is used for treating, preventing and diagnosing celiac disease. ImmusanT’s pipeline products are al …
  • SK Kaken Co Ltd (4628):企業の財務・戦略的SWOT分析
    SK Kaken Co Ltd (4628) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Tailored Brands, Inc.:企業の戦略・SWOT・財務情報
    Tailored Brands, Inc. - Strategy, SWOT and Corporate Finance Report Summary Tailored Brands, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Avid Technology Inc (AVID):企業の財務・戦略的SWOT分析
    Avid Technology Inc (AVID) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Boursorama Sa:企業の戦略・SWOT・財務分析
    Boursorama Sa - Strategy, SWOT and Corporate Finance Report Summary Boursorama Sa - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • GE Energy Power Conversion Group:企業の戦略的SWOT分析
    GE Energy Power Conversion Group - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major pr …
  • StealthGas Inc (GASS):石油・ガス:M&Aディール及び事業提携情報
    Summary StealthGas Inc (StealthGas) is an oil and gas shipping company that offers seaborne and oil and gas transportation services. The company provides transportation of petroleum and petrochemical gas products in liquefied forms. It transports byproducts of crude oil and natural gas including but …
  • Cargolux Airlines International S.A.:企業の戦略的SWOT分析
    Cargolux Airlines International S.A. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and majo …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆